YUHSpace: Dept. of Internal Medicine (내과학교실)

YUHSpace

BROWSE

YUHSpace1. College of Medicine (의과대학)Dept. of Internal Medicine (내과학교실)

Dept. of Internal Medicine (내과학교실)

Researcher List

Keyword Cloud

Journal Categories

Highly Cited Articles

Trastuzumab in combination with chemotherapy versus chemotherapy alone f...

Yung-Jue Bang ; Eric Van Cutsem ; Andrea Feyereislova ; Hyun C Chung ; Lin Sh... LANCET, Vol.376(9742) : 687-697, 2010

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

Jean-Charles Soria ; Yuichiro Ohe ; Johan Vansteenkiste ; Thanyanan Reungwetw... NEW ENGLAND JOURNAL OF MEDICINE, Vol.378(2) : 113-125, 2018

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer

S.J. Antonia ; A. Villegas ; D. Daniel ; D. Vicente ; S. Murakami ; R. Hui ; ... NEW ENGLAND JOURNAL OF MEDICINE, Vol.377(20) : 1919-1929, 2017

This table browses all dspace content
Issue Date	Title	Journal Title
2024	Causal effect of fasting serum glucose on atherosclerotic cardiovascular disease: a multivariable Mendelian randomization	EPIDEMIOLOGY AND HEALTH
2024	Impact of Intensive Blood Pressure Lowering After MultipleAttempt Endovascular Thrombectomy : a secondary analysis of the OPTIMAL-BP trial	INTERNATIONAL JOURNAL OF STROKE
2024	Fel d 1 specific IgE measurement for dog exclusive owners co-sensitized to dog and cat	WORLD ALLERGY ORGANIZATION JOURNAL
2024	Subgroup effects of ticagrelor monotherapy for acute coronary syndrome using individual patient data from the TICO and T-PASS trials	EUROPEAN HEART JOURNAL
2024	Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent/advanced ER-positive endometrioid endometrial cancer: Results from the phase 1a/1b EMBER study	GYNECOLOGIC ONCOLOGY
2024	Balloon-expandable cobalt chromium stent versus self-expandable nitinol stent for the Atherosclerotic Iliac Arterial Disease (SENS-ILIAC Trial) Trial: a randomized controlled trial	HEART AND VESSELS
2024	Sacituzumab govitecan in HR+HER2- metastatic breast cancer: the randomized phase 3 EVER-132-002 trial	NATURE MEDICINE
2024	Asia-Pacific Real-World Evolocumab Use, LDL-C Reduction, Physician Goals, and Patient Perceptions: HALES Observational Study	CARDIOLOGY AND THERAPY
2024	Mechanisms of allorecognition and xenorecognition in transplantation	Clinical Transplantation and Research
2024	Discovery of selective LATS inhibitors via scaffold hopping: enhancing drug-likeness and kinase selectivity for potential applications in regenerative medicine	RSC MEDICINAL CHEMISTRY
2024	Association between Coronary Artery Calcification and Carotid Plaque Using Health Check-Up Data	Journal of Neurosonology and Neuroimaging
2024	Combined inhibition of CDK4/6 and AKT is highly effective against the luminal androgen receptor (LAR) subtype of triple negative breast cancer	CANCER LETTERS
2024	Clinical Manifestations and Adverse Cardiovascular Events in Patients with Cardiovascular Symptoms after mRNA Coronavirus Disease 2019 Vaccines	YONSEI MEDICAL JOURNAL
2024	Epigenetic scars in regulatory T cells are retained after successful treatment of chronic hepatitis C with direct-acting antivirals	JOURNAL OF HEPATOLOGY
2024	Clinical characteristics and outcomes of kidney transplantation in autosomal dominant polycystic kidney disease patients	JOURNAL OF NEPHROLOGY
2024	Development of Clinically Validated Artificial fi cial Intelligence Model for Detecting ST-segment Elevation Myocardial Infarction	ANNALS OF EMERGENCY MEDICINE
2024	Association of moderate-to-vigorous physical activity with reduction of acute exacerbation in COPD patients using a dual ultra-long-acting bronchodilators	SCIENTIFIC REPORTS
2024	The association between transferrin saturation and all- cause mortality in chronic kidney disease: findings from Korean Cohort Study for Outcome in Patients with Chronic Kidney Disease	KIDNEY RESEARCH AND CLINICAL PRACTICE
2024	The impact of severe depression on the survival of older patients with end-stage kidney disease	KIDNEY RESEARCH AND CLINICAL PRACTICE
2024	ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial	CLINICAL CANCER RESEARCH